Changing how often a popular cancer therapy is delivered would reduce greenhouse gas emissions and improve environmental impact without decreasing cancer survival, according to a new analysis from ...
The number and frequency of intravesical instillations for non-muscle-invasive bladder cancer (NMIBC) impairs quality of life and needs to be reported in clinical trials.
AXS-12 reduced the frequency of cataplexy attacks per week compared with placebo (P =.017). Topline results were announced from a phase 3 trial evaluating AXS-12 (reboxetine) in patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results